Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/46451
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrekke, Kurt R.en_US
dc.contributor.authorHolmås, Tor Helgeen_US
dc.contributor.authorStraume, Odd Runeen_US
dc.date.accessioned2010-12-13en_US
dc.date.accessioned2011-06-29T11:19:22Z-
dc.date.available2011-06-29T11:19:22Z-
dc.date.issued2010en_US
dc.identifier.urihttp://hdl.handle.net/10419/46451-
dc.description.abstractWe study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. First, we construct a vertical differentiation model to analyze the impact of regulation on prices and market shares of brand-names and generics. Then, we exploit a detailed panel data set at product level covering several off-patent molecules before and after the policy reform. Off-patent drugs not subject to RP serve as our control group. We find that RP significantly reduces both brand-name and generic prices, and results in significantly lower brand-name market shares. Finally, we show that RP has a strong negative effect on average molecule prices, suggesting significant cost-savings, and that patients' copayments decrease despite the extra surcharges under RP.en_US
dc.language.isoengen_US
dc.publisher|aCenter for Economic Studies and Ifo Institute (CESifo) |cMunichen_US
dc.relation.ispartofseries|aCESifo working paper: Industrial Organisation |x3258en_US
dc.subject.jelI11en_US
dc.subject.jelI18en_US
dc.subject.jelL13en_US
dc.subject.jelL65en_US
dc.subject.ddc330en_US
dc.subject.keywordpharmaceuticalsen_US
dc.subject.keywordregulationen_US
dc.subject.keywordgeneric competitionen_US
dc.subject.stwPharmazeutisches Produkten_US
dc.subject.stwStaatliche Preispolitiken_US
dc.subject.stwPreiswettbewerben_US
dc.subject.stwProduktdifferenzierungen_US
dc.subject.stwGenerikaen_US
dc.subject.stwGesundheitskostenen_US
dc.subject.stwNorwegenen_US
dc.titleReference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experimenten_US
dc.typeWorking Paperen_US
dc.identifier.ppn641609000en_US
dc.rightshttp://www.econstor.eu/dspace/Nutzungsbedingungenen_US

Files in This Item:
File
Size
743.21 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.